| Metric | H2 FY26 | H1 FY26 | H2 FY25 |
|---|---|---|---|
| Revenue from operations | 32.2 | 14.4 | 14.8 |
| Other income | 0.1 | 0.0 | 0.1 |
| Total income | 32.3 | 14.4 | 14.9 |
| Profit before exceptional items & tax | 4.0 | 2.4 | 2.4 |
| Profit before tax | 4.0 | 2.4 | 2.4 |
| Net profit | 2.9 | 1.7 | 1.8 |
| Operating margin | 12.4% | 16.7% | 16.1% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +61.10% |
|---|---|
| Net profit, quarter on quarter | +70.60% |
| Revenue, year on year | +117.60% |
Source
Read the filing ↗
BSE results filing, BSE: 544529. Figures extracted from the filing.
Aptus Pharma Ltd: key numbers
- Share price
- ₹347.00
- Market cap
- ₹595.1 Cr
- Revenue (annual)
- ₹46.57 Cr
- Net profit (annual)
- ₹4.62 Cr
- P/E (TTM)
- 128.8×Sector 50.4×
- Promoter holding
- 72.89%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aptus Pharma Ltd
All →
20:13 IST
BSE
Annual General Meeting
Aptus Pharma Annual General Meeting
Aptus Pharma Ltd issued a corrigendum to its 16th AGM notice regarding inadvertent errors in the explanatory statement for item no. 3.
16:47 IST
BSE
Earnings Call
Aptus Pharma Earnings Call: Key Takeaways
Aptus Pharma (BSE SME) reports strong growth in FY26 following its 2025 listing. The company operates an asset-light, marketing-focused model with 250+ formulations across diverse therapeutic segments.